Adapting Clinical Chemistry Plasma as a Source for Liquid Biopsies

3
4 Spencer C. Ding[1], Jingru Yu[1], Tiepeng Liao[1], Lauren S. Ahmann[2], Yvette Y. Yao[3], Chandler
5 Ho[4], Linlin Wang[5], Benjamin A. Pinsky[1,6], Wei Gu[1, *]
6
7
8
[1] Department of Pathology, School of Medicine, Stanford University, Stanford, USA
[2] Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland,
Oregon, USA
[3] School of Medicine, University of British Columbia, Vancouver, Canada
[4] Clinical Laboratories, Stanford Health Care, Stanford, USA
[5] Department of Laboratory Medicine, School of Medicine, University of California San
Francisco, San Francisco, USA
[6] Department of Medicine, Division of Infectious Diseases and Geographic Medicine, School of
Medicine, Stanford University, Stanford, USA
18
19
20 * Corresponding author:
21
22 Wei Gu
23 Assistant Professor, Department of Pathology, Stanford University
24 3373 Hillview Ave, room 220
25 Palo Alto, CA 94304-1204
26 weigu@stanford.edu
27
28

Abstract

Background

Circulating cell-free DNA (cfDNA) has become a valuable analyte for molecular testing but requires specialized collection tubes or immediate processing. We investigated the feasibility of using residual plasma from heparin separators, which are routinely used in clinical chemistry, as an accessible and underutilized source for cfDNA testing.

Methods

We analyzed matched plasma samples collected in EDTA, Streck, and heparin separators in a Healthy Cohort (n = 5) and matched samples collected in EDTA and heparin separators from a Hospital Cohort derived from viral PCR-positive patients (n = 34). Whole-genome sequencing and genome-wide enriched methylation sequencing were performed to evaluate concordance across multiple benchmarks, including metagenomics, chromosomal copy number, methylome, and fragmentomics.

Results

In the Healthy Cohort, methylation patterns were correlated (Pearson's r = 0.92–0.93) between tube types, and fragmentation features were preserved with a modal size peak at 166 bp and a consistent top 10 end motif ranking across tube types (n = 5). In the Hospital Cohort, heparin separators showed a strong concordance with matched EDTA tubes for viral detection (n = 34, Pearson's r = 0.99), copy number alteration profiling (n = 6, Pearson's r = 0.86-0.98), and methylation patterns (n = 12, r = 0.83-0.93).

Conclusions

Residual plasma from routine clinical chemistry tests can provide a vast, untapped resource for cfDNA analysis.

Background

Plasma cell-free DNA (cfDNA) is widely used in clinical testing(1), including non-invasive prenatal testing (NIPT)(2–5), cancer testing(6–8), infectious disease testing(9,10), and organ transplantation monitoring(11,12). In cancer testing, cfDNA is actively studied for the detection of residual cancer disease(13) and early detection (14,15).

Reliable cfDNA analysis typically depends on specialized preservative tubes (e.g., Streck) or rapid processing of EDTA tubes(16). However, both methods limit accessibility by requiring specific tubes or on-call personnel, which adds costs and restricts cfDNA testing in resource-limited settings.

In contrast, heparin separators are standardly used in clinical settings, ubiquitous in everyday phlebotomy trays at many institutions for routine chemistry testing, such as the basic metabolic panel. For example, at our institution alone (Stanford Health Care), over 900,000 of these tubes are processed annually. These tubes contain a gel barrier that separates plasma from cellular components following routine centrifugation. They are typically handled through high-throughput, automated, and CLIA-compliant workflows that incorporate prompt centrifugation and refrigerated storage.

This study explores the potential utilization of millions of leftover plasma samples and the associated healthcare infrastructure as an untapped resource for cfDNA research and clinical testing. To assess the feasibility of using heparin separators for cfDNA testing, we conducted whole-genome sequencing (WGS) and the FLEXseq methylation assay(17) on paired samples collected from the same venipuncture in both heparin separators and gold standard EDTA (and/or Streck) tubes. Our evaluation spanned multiple benchmarks relevant to a broad assortment of cfDNA tests, including metagenomics(9,18), methylation profiling (17,19), copy number alterations (CNAs)(20), epigenetic tissue-of-origin mapping(19), and cfDNA fragmentomics(21).

Results

Heparin separators preserve cfDNA integrity under ideal conditions

To evaluate the potential of repurposing leftover plasma from heparin separators, we conducted a controlled comparison in the Healthy Cohort (n = 5) using matched samples collected from the same blood draw in heparin separators and in gold-standard EDTA and Streck tubes (Fig. 1a, Table S1).

Fragment size distributions were highly similar across all tube types, with a modal peak at ~166 bp, consistent with known cfDNA profiles (Fig. 1b)(4,24). End motif analysis of 256 4-mers showed comparable rankings (Fig. 1c), suggesting that heparin separators do not perturb fragmentation patterns when processed immediately.

To assess the preservation of epigenomic features, we calculated methylation levels at

individual CpG sites using the FLEXseq methylation assay's output. CpG sites with ≥30×

coverage showed strong correlations between heparin separator and EDTA (Pearson's r = 0.93,

Fig. 1d, left), and between heparin separator and Streck (r = 0.93, Fig. 1d, right). Tissue deconvolution revealed highly concordant cell type proportions across all collection tube types (Fig. 1e, P = 0.86, PERMANOVA), with consistent results across all five cases (Heparin separator versus EDTA: Pearson's r = 0.92-0.93; heparin separator versus Streck: Pearson's r = 0.92-0.93; Supplemental Fig. 1). These findings show that heparin separators preserve the biological status of methylation under ideal processing conditions.

To mimic clinical storage, we tested the impact of delayed processing. Blood from a healthy volunteer was collected into EDTA, heparin separator, and non-gel heparin tubes, then divided into two sets (Supplementary Fig. 2a). One set was processed immediately, while the other was refrigerated (4°C) for one hour before the first spin and an additional four days before the second spin. Fragment size profiles were identical (Supplementary Fig. 2b), confirming that refrigerated storage does not compromise cfDNA integrity.

Figure 1. Overall schematic and Healthy Cohort's comparative performance
a. Schematic illustration of the experimental design across two cohorts. The Healthy Cohort was a
controlled experiment where plasma samples from healthy volunteer donors were collected freshly in
EDTA, Streck, and heparin separators. The Hospital Cohort plasma samples were retrospectively
collected in EDTA and heparin separators as part of patient care and leftover from routine clinical testing.
The Hospital Cohort samples underwent an initial soft spin during the routine clinical workflow and then a
hard spin after refrigerated storage. Processed samples were analyzed using whole-genome sequencing
(WGS) and/or FLEXseq methylation testing.
b. Healthy Cohort fragment size distribution of cfDNA collected across the three tubes.
c. Healthy Cohort comparison of end motif rankings in heparin separator samples versus EDTA or Streck
tubes.
d. Healthy Cohort heatmap and correlation of methylation beta values in paired samples from a healthy
donor (P140). Heparin separators (y-axis) are compared to EDTA and Streck tubes (x-axis).
e. Healthy Cohort estimation of cell-type proportions using methylation deconvolution for each collection
tube.

Hospital Cohort: Residual plasma from Heparin separators after clinical usage

To evaluate the feasibility of heparin separator tubes for cfDNA analysis, we identified 34
matched pairs of viral PCR–positive plasma samples (viral load >1000 IU/mL) collected in both
heparin separator and EDTA tubes from the same blood draw. These cases were retrieved by
querying the electronic medical record systems at Stanford (n=28) and UCSF (n=6) for samples
that tested positive by the Clinical Virology Laboratories. All samples underwent cfDNA
extraction, followed by whole-genome sequencing (WGS) to evaluate viral load, copy number
alterations (CNAs), and fragmentation profiles, as well as methylation profiling via FLEXseq.

Leftover plasma from the heparin separators enables viral load detection

We performed metagenomic sequencing to compare viral load measurements and assess
concordance between plasma collected in EDTA and heparin separators (Fig. 2). WGS
achieved a median coverage of 4.52× (IQR: 1.76-5.08×). Viral read counts normalized to the
number of reads aligned to the human genome were highly correlated between plasma
collection tube types (Pearson's r = 0.99, $P < 0.001$), with no significant difference observed
(Wilcoxon signed-rank test, $P = 0.27$). This high level of concordance was consistently observed
across institutions and among distinct viral types.

Figure 2. Viral load correlation of the Hospital Cohort
Correlation of plasma viral DNA reads detected by whole genome sequencing in paired cases collected in EDTA and heparin separators. Samples were collected at two institutions (Stanford - blue, UCSF - red, EBV - circle, HHV6 - triangle, other virus - square). RPM: reads per million human-aligned reads.

Leftover plasma from the heparin separator enables copy number profiling

CNAs are commonly observed in cancer and can be detected in cfDNA as a surrogate marker for tumor burden. To evaluate whether heparin separators preserve CNA signals, we compared the genome-wide copy number profiles of samples from heparin separators and EDTA tubes. CNA profiles were generated using a 500 kbp bin size, with a median of 97.68 million reads per sample (range: 0.73–360.73 million). Representative genome-wide CNA plots from a matched pair (P171: heparin separator; P187: EDTA) revealed similar patterns of chromosomal gains and losses (Fig. 3a). Genome-wide $\log_2$ copy ratio deviations were concordant between tube types (Pearson's r = 0.97; Fig. 3b). Similar patterns and concordance were observed in other CNA-positive samples (n = 5, Pearson's r = 0.86–0.99; Supplementary Fig. 3). Tumor fraction estimates based on copy number also correlated strongly between matched samples (Pearson's r = 0.97; Fig. 3c). These findings demonstrate that plasma from heparin separators is suitable for CNA detection and tumor fraction estimation.

Figure 3. Copy number analysis of the Hospital Cohort

a. An example of genome-wide copy number profiles from Patient 34. Case P171 was collected in a heparin separator; Case P187 was collected in EDTA tube.
b. Comparison of $\log_2$ copy ratios between P171 and P187 based on 500 kb bin sizes.
c. Comparison of tumor fraction in paired cases (n=28 pairs) inferred from copy number analysis.

Correlated Methylation Profiling from Heparin Separator Plasma

To assess the reliability of methylation profiling across blood collection tube types, we analyzed the available residual matched plasma samples in the Hospital Cohort (n=12). Using FLEXseq(17), a high-resolution methylation assay, we observed strong genome-wide concordance of CpG methylation levels between heparin separator and EDTA tubes (P168: heparin separator, P185: EDTA tube; Pearson's r = 0.90; Fig. 4a; other cases in Supplementary Fig. 4). To evaluate the biological relevance of the cfDNA methylation profiles, we performed cell type deconvolution on the paired plasma(19). The results showed comparable tissue-of-origin proportions between plasma collected in heparin separator and EDTA tubes (Fig. 4b). These findings demonstrate that cfDNA methylation signatures are well preserved in heparin separator plasma and are reliable for epigenomic applications such as cell-of-origin estimation.

Figure 4. Methylation correlation and cell type deconvolution analysis in the Hospital Cohort

a. Heatmap showing methylation beta values in paired samples (Patient 31, P185 versus P168).

b. Estimated cell-type proportions in the paired samples (P185 versus P168).

Comparable cfDNA yield deduced from the sequencing result

We quantified cfDNA concentrations (normalized to plasma volume) in the 25 matched pairs
from the Healthy Cohort and the Hospital Cohort with sufficient leftover DNA. Qubit
measurements revealed variability across samples (0.14–43.19 ng/mL; Fig. 5a & Fig. 5b) and
poor correlation between EDTA and heparin separator data. However, Qubit measurements are
related to both addressable (intact short fragments) and non-addressable (genomic length or
broken) DNA, whereas NGS output is related to only addressable DNA.

To enable precise measurements of the addressable DNA, we spiked in lambda DNA at a
constant quantity across all samples at the beginning of the library preparation and normalized
human-aligned read counts to this internal control. This strategy produces a measure
(Human/Lambda ratio) proportional to the addressable DNA content of the sample. This
normalized ratio yielded strong concordance between EDTA and heparin separator samples (R^2
= 0.998; Fig. 5c), indicating that library preparation effectively mitigated preanalytical variability.

Figure 5. Correlation of DNA quantity
a. Scatter plot of the normalized extracted DNA concentration based on Qubit reading. Data is from 20
individuals of the Hospital Cohort and 5 individuals from the Healthy Cohort using heparin separators and
EDTA tubes. Normalized DNA concentration (ng/mL plasma) in heparin separator samples (y-axis) vs.
EDTA tube samples (x-axis), quantified by dsDNA Qubit and normalized to the input volume of plasma.
b. Scatter plot of the log-scale normalized concentration (Qubit readout) in the heparin separators (y-axis)
vs. the EDTA tube samples (x-axis).
c. Scatter plot of the ratio of human reads to a constant lambda phage DNA spike-in detected in the
heparin separator sample (y-axis) vs. the EDTA tube samples. This spike-in measurement is proportional
to the addressable DNA quantity of the sample.

Leftover plasma from the heparin separator alters fragmentation profiles

Fragmentation features of cfDNA, such as size distribution and end motifs, have been linked to
nuclease activity and are known to reflect host physiology and pathology(25–27). To evaluate
whether heparin separators preserve these fragmentation features, we examined two well-
characterized fragmentomic features: size distribution and end-motif. Both EDTA and heparin
separator plasma samples exhibited expected peak sizes near 70 bp and 170 bp
(Supplementary Fig. 5). However, heparin separator plasma showed a modest increase in short
fragments and a slightly diminished ~166 bp peak, indicating a shorter size distribution. Analysis

of 4-mer motifs at the 5′ ends of cfDNA fragments revealed significant differences in four of the
six most frequent motifs (i.e., CCCA, CCAG, CCTG, and CAAA; $P < 0.05$, paired Student's t-
test), suggesting disrupted cleavage preference. These altered fragmentation profiles in the
Hospital Cohort suggest that plasma samples collected in heparin separators may have
influenced cfDNA fragmentation signatures. Given that the fragmentation profiles were
concordant in the Healthy Cohort, the differences seen here may be due to degradation during
delays in clinical lab processing after blood collection and prior to refrigerated storage.

233   Discussion

Our study explores the untapped potential of repurposing residual plasma from heparin
separators as a practical and underutilized resource for circulating cfDNA-based research and
diagnostic applications. Using matched samples from a Healthy Cohort and a real-world
Hospital Cohort, we demonstrate that the leftover plasma is suitable for metagenomic viral
detection, copy number profiling, and genome-wide methylation analysis, with performance
comparable to gold-standard collection methods.

Although heparin separators have been previously used in COVID-19 cfDNA studies(28,29),
their performance has not been systematically evaluated against standard collection methods.
Historically, concerns about heparin-induced PCR inhibition and genomic DNA leakage from
cells have limited the use of heparin tubes, although the available evidence remains
inconclusive. For instance, Lo et al. reported no significant difference in DNA concentration
between EDTA and heparin tubes when plasma was processed promptly within 2 hours after
blood collection, suggesting minimal gDNA release(30). In contrast, Gerber et al. reported
elevated cfDNA levels in heparin tubes compared to specialized tubes such as PAXgene,
Roche cfDNA, and Streck, even at time point 0(31). The results in our Healthy Cohort suggest
no significant differences in samples immediately processed or refrigerated at 4°C. Unlike
earlier studies that relied on PCR-based assays and used standard heparin tubes, our study
utilized heparin separators with a gel barrier to physically separate plasma from cells. Moreover,
modern cfDNA sequencing workflows include multiple purification steps that could effectively
reduce heparin interference on PCR and preferentially retain short cfDNA fragments, minimizing
the impact of gDNA contamination on downstream analysis.

Fragmentation profiles were consistent across tube types in the Healthy Cohort but variable in
the Hospital Cohort, likely reflecting preanalytical differences before laboratory processing. Prior
research has shown that incubating blood with heparin at room temperature for 6 hours alters
cfDNA fragmentation profiles, possibly due to heparin-induced nucleosomal disruption and
enhanced DNase I activity(32). In contrast, prompt refrigeration in the Healthy Cohort preserved
cfDNA integrity, potentially by inhibiting nuclease activity.

Our study demonstrates the feasibility of repurposing residual plasma from heparin separators
for sequencing-based cfDNA analysis, offering a collection method that integrates seamlessly

into existing clinical workflows. By utilizing samples already collected during routine care, this
approach eliminates the need for additional venipuncture and enables retrospective access to
clinically important cases, including those where informed consent could not be obtained at the
time of collection. While promising, the approach is constrained by the limited residual plasma
volume (0.5–1.5 mL), which may not meet the input requirements of applications such as
minimal residual disease detection. Moreover, variability in transport and storage conditions
prior to processing, as observed in the Hospital Cohort, can affect cfDNA integrity. The
observed alteration in fragmentation profiles highlights the need for cold-chain transportation
protocols to minimize variability and maintain cfDNA quality. Future studies should also validate
this approach in larger, clinically diverse populations and assess its integration into routine
preanalytical workflows.

In summary, residual plasma from heparin separators can serve as a viable source for cfDNA
analysis, with stable results for copy number variation, viral load, and methylation profiling
despite fragmentomic sensitivity to preanalytical variability. Repurposing residual plasma from
routine blood tests could greatly simplify and expand cfDNA accessibility across a diverse range
of patients.

Methods
279

Study design and subject selection
280

Healthy Cohort: Five healthy adult volunteers (28–40 years old) donated blood with informed
consent as approved under Stanford IRB (71230). Whole blood was collected from each donor
via a single venipuncture into three tube types: EDTA, Streck, and heparin separators.

Hospital Cohort: Clinical samples were from two institutions, Stanford and UCSF. At Stanford,
28 matched pairs of remnant samples were obtained (collected between 2022 and 2025) under
a no-patient-contact protocol (IRB 58461). Patients gave written consent for the use of residual
clinical samples. Patients positive for Epstein-Barr virus (EBV), human herpesvirus 6 (HHV6),
BK virus, adenovirus, or Torque Teno Virus were identified based on routine clinical viral PCR
testing performed by the Stanford or UCSF Clinical Virology Laboratories. These viral tests were
typically conducted in the context of post-transplant surveillance or infectious disease
diagnostics. Residual EDTA plasma samples were processed by the clinical laboratory within
four hours of collection. Matched heparin separator plasma specimens drawn at the same time
were retrieved from the Stanford Clinical Chemistry Laboratory. Only matched plasma pairs with
volumes exceeding 0.5 mL were included in the study. Additional sample pairs from UCSF (n =
6) were obtained (collected between 2017 and 2020) under a similar no-patient-contact IRB
protocol (CA-0161925).

Sample collection and processing
297

Hospital Cohort: Upon arrival, plasma samples in EDTA tubes and heparin separators were
immediately centrifuged at 1300 g for 10 minutes using a Cobas 8100 automated workflow.

Following completion of routine clinical testing, the residual plasma is stored and transported at
approximately 4°C for up to 8 days before further processing. EDTA plasma was separated into
a different container, and heparin separator plasma was kept in the same original collection
tube, but physically isolated above the gel separator. These procedures were conducted by the
hospital staff as part of routine clinical care in accordance with a CLIA-compliant standard
operating procedure. The plasma supernatant was identified by a research team, deidentified,
transferred to our research lab at refrigeration, and subjected to a second centrifugation at
16,000 × g for 10 minutes. Plasma aliquots from both EDTA tubes and heparin separators were
stored at –80°C until downstream analysis. UCSF cases were processed as previously
described(18).

DNA extraction

311 Cell-free DNA (cfDNA) was extracted from 0.5 to 1 mL of plasma using the Maxwell RSC 48
312 instrument (Promega) with the Maxwell RSC ccfDNA Plasma Kit (AS1480), following the
313 manufacturer's instructions. Samples were processed in parallel in batches. cfDNA
314 concentrations were quantified using the Varioskan spectrophotometer (Thermo Fisher
315 Scientific). UCSF cases were extracted as previously described(18).

Whole genome sequencing DNA library preparation

A median of 18.65 ng of extracted cfDNA (range: 3.00- 51.70 ng) and 2.5 ng of fragmented
Lambda DNA (NEB #N3013) as internal control was used for whole-genome sequencing (WGS)
library preparation with the NEBNext Ultra II DNA Library Prep Kit (New England Biolabs,
#E7645L), following the manufacturer's protocol. PCR primers were NEBNext Multiplex Oligos
for Illumina (NEB #E6444L). Adapter-ligated DNA was amplified for 20 cycles using the Q5
master mix, following the manufacturer's instructions. UCSF cases were processed as
previously described(18).

FLEXseq DNA library preparation

325 FLEXseq DNA libraries were prepared as previously described. Briefly, extracted cfDNA
326 molecules were adapter-ligated, dephosphorylated, digested with MspI (NEB, #R0106T),
327 adapter-ligated a second time with custom adapters, subjected to NEBNext Enzymatic Methyl-
328 seq Conversion Module (New England Biolabs, #E7125L), and PCR amplified.

Sequencing and alignment

Paired-end sequencing was performed on the NovaSeq X platform (Illumina) at the University of
Chicago Genomics Core Facility using the 25B Reagent Kit (300 cycles). For WGS data,
sequencing adapters were trimmed using Cutadapt v3.5 with the following parameters: -a
AGATCGGAAGAGC -A AGATCGGAAGAGC --minimum-length 25. Trimmed reads were
aligned to the hg38 human reference genome, as well as EBV, HHV6, and other viral genomes
using BWA v0.7.17. PCR duplicates were removed using Samtools.

FLEXseq data were processed following the protocol described by Yu et al.(17). Briefly, reads
were trimmed to remove adapters and filtered based on quality scores. High-quality reads were
aligned to the hg38 genome using Bismark v0.23.0. Unconverted and duplicated reads were
removed using Bismark. All SNP-containing regions were masked for de-identification using
Bedtools.

Viral load analysis: The ratio of reads aligned to viral genomes (e.g., EBV, HHV6) relative to
every one million reads aligned to the human genome (hg38) was calculated and log-
transformed. Pearson correlation analysis was performed between matched tube types, with the
linear regression constrained to pass through the origin (0, 0).

CNA analysis: Copy number alterations were analyzed using ichorCNA on autosomal
chromosomes(22). HMMcopy's readCounter was used to generate 500 kb bin-level Wig files
from aligned BAM files, which included only reads with a mapping quality score >20. Reference
files for GC content (gcWig), mappability score (mapWig), and centromere positions were
obtained from the ichorCNA GitHub repository corresponding to the selected bin size. Panel-of-
normal (PoN) Wig files were generated separately using the cases in the Healthy Cohort in the
EDTA and heparin separator groups, respectively.

Tumor purity was estimated based on log2 ratio outputs from ichorCNA using previously
reported calculations(23).

$$TumorPurity(\%) = \frac{1 - 2^{(log_2\ ratio)}}{1 - \frac{(assumed\ ploidy)}{2}} \times 100$$

Methylation correlation analysis: Methylation calls were extracted using the

bismark_methylation_extractor. For each CpG site, the methylation level was calculated as the

ratio of methylated reads to total coverage depth. CpG sites with coverage ≥30× were retained

for correlation analysis between matched samples.

Tissue-of-origin analysis: Tissue-of-origin deconvolution was performed using cell type-
specific unmethylated markers as previously described by Loyfer et al.(19). The top 250
unmethylated CpG markers for each cell type were extracted from the reference dataset.
Markers located on sex chromosomes or overlapping with common single nucleotide
polymorphisms (SNPs) were excluded. Deconvolution was conducted using the uxm function
based on a panel of nine reference cell types: B cells, T cells, natural killer (NK) cells,
granulocytes, monocytes/macrophages, endothelial cells, erythroid progenitors,
megakaryocytes, and hepatocytes.

cfDNA fragmentomics: Fragment size distributions were generated for each sample by
calculating the frequency across fragment lengths between 50 and 600 bp. End motif

frequencies were also calculated for each sample. The Shapiro-Wilk test was performed
separately for each motif in different tubes (EDTA, Heparin separator, and Streck) to assess
whether the frequency distributions followed a normal distribution. For the Healthy Cohort,
differences among the three collection tubes were evaluated using the Friedman test. For the
Hospital Cohort, statistical significance between tube types was assessed using the Paired
Student's t-test. To control the false discovery rate (FDR), multiple testing corrections were
applied using the Benjamini-Hochberg procedure across all tested motifs. Significance was
determined based on FDR-adjusted *P*-values.

Data Availability

378   Raw WGS and genome-wide enriched methylation sequencing data are available for the
379   Healthy Cohort (n = 5) with informed consent. FASTQ files were uploaded to the Sequence
380   Read Archive (SRA), with the Bioproject ID of PRJNA1260066. Viral reads detailed statistic files
381   (n=28), methylation calls (n=17), copy number plots (n=6), and fragment length files (n=34) are
382   available on Zenodo (https://doi.org/10.5281/zenodo.15367094).

Conflict of Interest

384   The authors J.Y., L.S.A., Y.Y.Y., and W.G. filed a patent application related to FLEXseq
385   (PCT/US2024/056111).

Acknowledgements

This work was funded by an NIH K08 (CA230156) grant, a Burroughs-Wellcome CAMS Award
to WG. We thank the members of the Stanford Clinical Molecular Genetic Pathology, Clinical
Virology, and Clinical Chemistry Laboratories, and UCSF Clinical Virology and Clinical
Chemistry Laboratories for saving residual specimens. We thank Debbie Chan and Dianna Ng
for their critical insights at the inception of this project and Ruben Luo for facilitating Clinical
Chemistry collections at Stanford. We thank the University of Chicago Genomics Facility (RRID:
SCR_019196) for Novaseq sequencing.

References

1. Loy C, Ahmann L, De Vlaminck I, Gu W. Liquid Biopsy Based on Cell-Free DNA and RNA. Annu Rev Biomed Eng. 2024;26:169–95.

2. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485–7.

3. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. PNAS. 2008;105:16266–71.

4. Lo YMD, Chan KCA, Sun H, Chen EZ, Jiang P, Lun FMF, et al. Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. Science Translational Medicine. American Association for the Advancement of Science; 2010;2:61ra91-61ra91.

5. Fan HC, Gu W, Wang J, Blumenfeld YJ, El-Sayed YY, Quake SR. Non-invasive prenatal measurement of the fetal genome. Nature. Nature Publishing Group; 2012;487:320–4.

6. Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer. New England Journal of Medicine. Massachusetts Medical Society; 2017;377:513–22.

7. Chung DC, Gray DM, Singh H, Issaka RB, Raymond VM, Eagle C, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. New England Journal of Medicine. Massachusetts Medical Society; 2024;390:973–83.

8. Heitzer E, Ulz P, Geigl JB. Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clinical Chemistry. 2015;61:112–23.

9. Gu W, Miller S, Chiu CY. Clinical Metagenomic Next-Generation Sequencing for Pathogen Detection. Annual Review of Pathology: Mechanisms of Disease. Annual Reviews; 2019;14:319–38.

10. Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4:663–74.

11. De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, et al. Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection. Science Translational Medicine. American Association for the Advancement of Science; 2014;6:241ra77-241ra77.

12. Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, et al. Cell-Free DNA and Active Rejection in Kidney Allografts. J Am Soc Nephrol. 2017;28:2221–32.

13. Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science. 2020;

14. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and
specific multi-cancer detection and localization using methylation signatures in cell-free
DNA. Annals of Oncology. 2020;31:745–59.

15. Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, et al. Evaluation of cell-
free DNA approaches for multi-cancer early detection. Cancer Cell. 2022;40:1537-
1549.e12.

16. Meddeb R, Pisareva E, Thierry AR. Guidelines for the Preanalytical Conditions for
Analyzing Circulating Cell-Free DNA. Clinical Chemistry. 2019;65:623–33.

17. Yu J, Ahmann LS, Yao YY, Gu W. Enriched Methylomes of Low-input and Fragmented
DNA Using Fragment Ligation EXclusive Methylation Sequencing (FLEXseq). bioRxiv.
2024;2024.11.28.625942.

18. Gu W, Deng X, Lee M, Sucu YD, Arevalo S, Stryke D, et al. Rapid pathogen detection by
metagenomic next-generation sequencing of infected body fluids. Nat Med. 2021;27:115–
24.

19. Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA
methylation atlas of normal human cell types. Nature. 2023;613:355–64.

20. Lenaerts L, Vandenberghe P, Brison N, Che H, Neofytou M, Verheecke M, et al.
Genomewide copy number alteration screening of circulating plasma DNA: potential for the
detection of incipient tumors. Ann Oncol. 2019;30:85–95.

21. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of cell-
free DNA in liquid biopsies. Science. 2021;372:eaaw3616.

22. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al.
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with
metastatic tumors. Nat Commun. Nature Publishing Group; 2017;8:1324.

23. Gu W, Talevich E, Hsu E, Qi Z, Urisman A, Federman S, et al. Detection of cryptogenic
malignancies from metagenomic whole genome sequencing of body fluids. Genome Med.
2021;13:98.

24. Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Analysis of the Size
Distributions of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing. Clinical
Chemistry. 2010;56:1279–86.

25. Jiang P, Sun K, Peng W, Cheng SH, Ni M, Yeung PC, et al. Plasma DNA End-Motif
Profiling as a Fragmentomic Marker in Cancer, Pregnancy, and Transplantation. Cancer
Discovery. 2020;10:664–73.

26. Ding SC, Lo YMD. Cell-Free DNA Fragmentomics in Liquid Biopsy. Diagnostics.
Multidisciplinary Digital Publishing Institute; 2022;12:978.

27. Hu X, Ding SC, Jiang P. Emerging frontiers of cell-free DNA fragmentomics. Extracell
Vesicles Circ Nucl Acids. 2022;3:380–92.

28. Cheng AP, Cheng MP, Gu W, Sesing Lenz J, Hsu E, Schurr E, et al. Cell-free DNA tissues
of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury
related to COVID-19 severity. Med. 2021;2:411-422.e5.

29. Hoeter K, Neuberger E, Fischer S, Herbst M, Juškevičiūtė E, Enders K, et al. Evidence for
the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: a
retrospective pilot study. PeerJ. PeerJ Inc.; 2023;11:e16072.

30. Lam NYL, Rainer TH, Chiu RWK, Lo YMD. EDTA is a better anticoagulant than heparin or
citrate for delayed blood processing for plasma DNA analysis. Clin Chem. 2004;50:256–7.

31. Gerber T, Taschner-Mandl S, Saloberger-Sindhöringer L, Popitsch N, Heitzer E, Witt V, et
al. Assessment of Pre-Analytical Sample Handling Conditions for Comprehensive Liquid
Biopsy Analysis. J Mol Diagn. 2020;22:1070–86.

32. Han DSC, Ni M, Chan RWY, Chan VWH, Lui KO, Chiu RWK, et al. The Biology of Cell-free
DNA Fragmentation and the Roles of DNASE1, DNASE1L3, and DFFB. The American
Journal of Human Genetics. Elsevier; 2020;106:202–14.

Supplementary Figures

Supplementary Figure 1. Healthy Cohort methylation correlation and cell type deconvolution

Heatmap and correlation of methylation beta values with cell type deconvolution results in paired samples from five healthy donors.

Supplementary Figure 2. Healthy Cohort size distribution of cfDNA in EDTA and heparin tubes over time mimicking the clinical workflow

a) Schematic of the time-lapsed controlled experiment mimicking the clinical workflow.

b) The fragment size distribution of cfDNA across all conditions. "0 min" represents immediate centrifugation, while "1 h" indicates samples stored at 4°C for 1 hour before the soft spin and for 4 days at 4°C before the hard spin.

505 **Supplementary Figure 3. Copy number analysis across Hospital Cohort cases**

506 Comparison of other CNA-positive profiles of paired cases in the Hospital Cohort (n=5).

Supplementary Figure 4. Methylation correlation across Hospital Cohort cases

Heatmaps of methylation beta values in paired samples collected from 11 virus-positive patients in the Hospital Cohort. One additional case is shown in Figure 4.

Supplementary Figure 5. Fragmentomic patterns of the Hospital Cohort

a. Average cfDNA fragment size distribution collected in EDTA tubes and heparin separators.

b. Average end motif frequency comparison between EDTA tubes and heparin separators, highlighting the top six motifs: CCCA, CCAG, CCTG, CCCT, CCAT, and CAAA.